MIT's 'Mini Livers' Could Revolutionize Treatment for Failing Organs

MIT engineers have created injectable 'mini livers' that could help patients with failing liver function. These tiny clusters of liver cells are designed to work alongside the body's own organ, rather than replace it. Tests in mice show they can survive for months while producing vital proteins.

The human liver carries out around 500 essential tasks, most handled by cells called hepatocytes. When the organ fails, many patients cannot get a transplant due to health issues or a shortage of donated livers. In the US alone, over 10,000 people with chronic liver disease are currently waiting for a transplant.

Between 2021 and 2025, only 35,000–40,000 US patients received liver transplants—around 8,000–9,000 per year. Donor organs remain scarce, relying heavily on young adult deaths from accidents or overdoses. The new 'mini livers' aim to bridge this gap by acting as 'satellite livers' that boost function without surgery.

In early tests, the injected cells stayed alive in mice for at least two months. They continued producing key liver proteins, suggesting they could provide long-term support for damaged organs.

The technology offers a potential solution for patients who cannot access transplants or face long waits. If successful in humans, these injectable cells could ease pressure on donor organ shortages. Further trials will determine their safety and effectiveness in people.